The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema

APEC-0011

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema

2005-09-01

2005-09-01

2006-05-01

Withdrawn

Early phase I

Inclusion Criteria: * Type 2 diabetes * Macular edema involving the center of the macula demonstrated on OCT * Clear ocular media * Untreated patients * Older than 45 years * BCVA of the fellow eye at least 20/100 Exclusion Criteria: * Renal diabetic disease, uncontrolled hypertension or stroke history * Other ocular disease * Ocular surgery excepting uncomplicated phacoemulsification * History of photocoagulation (panretinal or focal) * History of another intravitreal treatment (like triamcinolone)

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}

2024-06-03